Ver el registro simple Dublin Core del ítem
Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies
dc.contributor.author | Razquin, Cristina | |
dc.contributor.author | Ruiz-Canela, Miguel | |
dc.contributor.author | Clish, Clary B. | |
dc.contributor.author | Li, Jun | |
dc.contributor.author | Toledo, Estefanía | |
dc.contributor.author | Dennis, Courtney | |
dc.contributor.author | Liang, Liming | |
dc.contributor.author | Salas-Huetos, Albert | |
dc.contributor.author | Pierce, Kerry A. | |
dc.contributor.author | Guasch-Ferre, Marta | |
dc.contributor.author | Corella, Dolores | |
dc.contributor.author | Ros, Emilio | |
dc.contributor.author | Estruch, Ramon | |
dc.contributor.author | Gomez-Gracia, Enrique | |
dc.contributor.author | Fito, Montserrat | |
dc.contributor.author | Lapetra, Jose | |
dc.contributor.author | Romaguera, Dora | |
dc.contributor.author | Alonso-Gomez, Angel | |
dc.contributor.author | Serra-Majem, Lluis | |
dc.contributor.author | Salas-Salvado, Jordi | |
dc.contributor.author | Hu, Frank B. | |
dc.contributor.author | Martinez-Gonzalez, Miguel A. | |
dc.date.accessioned | 2021-08-25T11:44:42Z | |
dc.date.available | 2021-08-25T11:44:42Z | |
dc.date.issued | 2019-11-13 | |
dc.identifier.citation | Razquin C, Ruiz-Canela M, Clish CB, Li J, Toledo E, Dennis C, et al. Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies. Cardiovasc Diabetol. 2019 Nov 13;18(1):151. | en |
dc.identifier.uri | http://hdl.handle.net/20.500.13003/13075 | |
dc.description.abstract | Background The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography-tandem mass spectrometry, at baseline and after 1-year of intervention. Results In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06-1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05-1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003 | en |
dc.language.iso | eng | en |
dc.publisher | BMC | en |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Cardiovascular Diseases | * |
dc.subject.mesh | Diabetes Mellitus, Type 2 | * |
dc.subject.mesh | Aged, 80 and over | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Randomized Controlled Trials as Topic | * |
dc.subject.mesh | 2-Aminoadipic Acid | * |
dc.subject.mesh | Risk Assessment | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Lysine | * |
dc.subject.mesh | Risk Reduction Behavior | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Male | * |
dc.subject.mesh | Pipecolic Acids | * |
dc.subject.mesh | Biomarkers | * |
dc.subject.mesh | Prospective Studies | * |
dc.subject.mesh | Time Factors | * |
dc.subject.mesh | Female | * |
dc.subject.mesh | Risk Factors | * |
dc.subject.mesh | Treatment Outcome | * |
dc.subject.mesh | Diet, Mediterranean | * |
dc.subject.mesh | Primary Prevention | * |
dc.subject.mesh | Incidence | * |
dc.title | Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies | en |
dc.type | research article | en |
dc.subject.decs | Dieta Mediterránea | * |
dc.subject.decs | Incidencia | * |
dc.subject.decs | Resultado del Tratamiento | * |
dc.subject.decs | Biomarcadores | * |
dc.subject.decs | Factores de Tiempo | * |
dc.subject.decs | Femenino | * |
dc.subject.decs | Conducta de Reducción del Riesgo | * |
dc.subject.decs | Masculino | * |
dc.subject.decs | Factores de Riesgo | * |
dc.subject.decs | Humanos | * |
dc.subject.decs | Persona de Mediana Edad | * |
dc.subject.decs | Ácidos Pipecólicos | * |
dc.subject.decs | Estudios Prospectivos | * |
dc.subject.decs | Lisina | * |
dc.subject.decs | Anciano | * |
dc.subject.decs | Medición de Riesgo | * |
dc.subject.decs | Anciano de 80 o más Años | * |
dc.subject.decs | Diabetes Mellitus Tipo 2 | * |
dc.subject.decs | Prevención Primaria | * |
dc.subject.decs | Enfermedades Cardiovasculares | * |
dc.subject.decs | Ensayos Clínicos Controlados Aleatorios como Asunto | * |
dc.subject.decs | Ácido 2-Aminoadípico | * |
dc.description.fundingtext | This research was supported by the National Institutes of Health HL118264, R01DK102896 and 2R01HL118264; Instituto de Salud Carlos III, Madrid, Spain: RD06/0045, RTIC G03/140, and CIBERobn (CB06/03). | en |
dc.identifier.doi | 10.1186/s12933-019-0958-2 | |
dc.identifier.essn | 1475-2840 | |
dc.identifier.pmid | 31722714 | |
dc.identifier.pui | L629863561 | |
dc.identifier.scopus | 2-s2.0-85074961499 | |
dc.identifier.wos | 000497753100001 | |
dc.issue.number | 1 | en |
dc.journal.title | Cardiovascular Diabetology | en |
dc.page.initial | 151 | en |
dc.relation.publisherversion | https://dx.doi.org/10.1186/s12933-019-0958-2 | en |
dc.rights.accessRights | open access | en |
dc.subject.keyword | Biomarkers | en |
dc.subject.keyword | Metabolites | en |
dc.subject.keyword | Cardiovascular disease | en |
dc.subject.keyword | Type 2 diabetes | en |
dc.subject.keyword | Dietary intervention | en |
dc.volume.number | 18 | en |